- Home
- MNRO vs BCAX Comparison
MNRO vs BCAX Comparison
Compare MNRO & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNRO
- BCAX
- Stock Information
- Founded
- MNRO 1957
- BCAX 2018
- Country
- MNRO United States
- BCAX United States
- Employees
- MNRO N/A
- BCAX N/A
- Industry
- MNRO Automotive Aftermarket
- BCAX
- Sector
- MNRO Consumer Discretionary
- BCAX
- Exchange
- MNRO Nasdaq
- BCAX NYSE
- Market Cap
- MNRO 473.8M
- BCAX 541.0M
- IPO Year
- MNRO 1991
- BCAX 2024
- Fundamental
- Price
- MNRO $14.09
- BCAX $10.53
- Analyst Decision
- MNRO Buy
- BCAX Strong Buy
- Analyst Count
- MNRO 4
- BCAX 7
- Target Price
- MNRO $20.75
- BCAX $29.17
- AVG Volume (30 Days)
- MNRO 991.8K
- BCAX 313.5K
- Earning Date
- MNRO 07-30-2025
- BCAX 08-16-2025
- Dividend Yield
- MNRO 7.95%
- BCAX N/A
- EPS Growth
- MNRO N/A
- BCAX N/A
- EPS
- MNRO N/A
- BCAX N/A
- Revenue
- MNRO $1,203,187,000.00
- BCAX N/A
- Revenue This Year
- MNRO $1.31
- BCAX N/A
- Revenue Next Year
- MNRO $2.56
- BCAX N/A
- P/E Ratio
- MNRO N/A
- BCAX N/A
- Revenue Growth
- MNRO N/A
- BCAX N/A
- 52 Week Low
- MNRO $12.20
- BCAX $7.80
- 52 Week High
- MNRO $30.95
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- MNRO 43.00
- BCAX N/A
- Support Level
- MNRO $12.26
- BCAX N/A
- Resistance Level
- MNRO $17.17
- BCAX N/A
- Average True Range (ATR)
- MNRO 1.18
- BCAX 0.00
- MACD
- MNRO -0.23
- BCAX 0.00
- Stochastic Oscillator
- MNRO 37.27
- BCAX 0.00
About MNRO Monro Inc.
Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.